Journal article
Recombinant Factor VIII Fc Fusion Protein for First-time Immune Tolerance Induction: Final Results of the verITI-8 Study
Abstract
Inhibitor development remains a major challenge in factor VIII (FVIII) replacement therapy. verITI-8 is the first prospective study of a recombinant FVIII Fc fusion protein (rFVIIIFc; efmoroctocog alfa) for first-time immune tolerance induction (ITI) in males with severe hemophilia A and high-titer inhibitors (historical peak ≥5 Bethesda units [BU]/mL). In this single-arm, open-label, multicenter study, screening was followed by ITI (rFVIIIFc …
Authors
Malec LD; Van Damme A; Chan AK; Spasova M; Jain N; Sensinger C; Dumont J; Lethagen S; Carcao M; Peyvandi F
Journal
Blood, Vol. 141, No. 16, pp. 1982–1989
Publisher
American Society of Hematology
Publication Date
April 20, 2023
DOI
10.1182/blood.2022017780
ISSN
0006-4971